EFFECTIVE DATE: June 14, 2021
ISSUE #: 1
PRESIDENT: Loren J. Blanchard
This PS provides guidelines for the administration of the University Faculty Development
Award (FDA) program at the University of Houston–Downtown. The FDA program
provides small project awards to support and enhance the University's educational mission
and enrich its faculty. Awards are competitive and will be designated to projects that
support faculty development and agency. The funding and assurance of institutional
compliance for this program will be managed by the Associate Vice President for Faculty,
Research and Sponsored Programs (AVP–FRSP).
2.1 Faculty Development: Activities and programming that develops faculty
knowledge, skills and agency in the areas of teaching, service, scholarship,
leadership and other areas that intersect with the professoriate. Faculty
Development does not include the execution of a particular research, scholarly, or
creative project; funding for the research/scholarly/creative enterprise is provided
by the Organized Research and Creative Activities (ORCA) Program (PS
2.2 Project Award: Amount of funding made to support a project. The maximum
award may vary between award cycles, but is limited to a maximum of 10% of the
total funds available in the award cycle. The maximum award will be listed on the
Award Announcement for the funding cycle.
2.3 Educational Mission: Defined here in accordance with the university, college,
department, and/or program mission statement that is in place in the cycle of the
announced call for proposals.
3.1 Proposal Requirement
3.1.1 To qualify for internal funding through the FDA Program, a faculty member
must submit a complete Faculty Development Award Request Form. The proposal must follow the format described in the Format For FDA Request Form and must provide all of the information required therein.
3.2 Proposal Eligibility and Criteria for Proposal Evaluation
3.2.1 Eligible proposals for the FDA Program must fall within the definition
presented in section 2.1. Faculty Development does not include the
execution of a research, scholarly, or creative project.
3.2.2 To qualify for internal funding through the FDA Program, each proposal
will be evaluated using criteria listed on the FDA Evaluation Rubric. The
rubric may be modified at the judgment and discretion of the University
FDA Committee. The rubric that will be used to score proposals in a given
funding cycle will be made available to faculty at the time the Request for
Proposals and FDA Request Form documents are sent to faculty and staff
who are eligible for the award.
3.2.3 The University FDA Committee that evaluates and scores submitted
proposals will consider only proposals that clearly meet the definition in
Section 2.1. It is the responsibility of the applicant to demonstrate that the
proposed activities meet this definition.
3.3 Limitations and Unallowable Expenses
3.3.1 Expenses connected with student support, faculty compensation, and faculty
release time are not supported by Faculty Development Awards.
3.3.2 For proposals that request funds for domestic conference travel, awards may
only be granted where the proposer is unable to obtain full funding from
other sources (including department travel budgets). The applicant should
note in the submitted documentation that the funds requested from FDA for
domestic conference travel are not available from the applicant’s
department. This restriction is not applicable to FDA requests for
international conference travel funds, since department funds may generally
not be used for international travel.
3.3.3 Funding requests to advance and improve curriculum through the purchase
of equipment or supplies, guest speakers, and software should be made only
when funds are unavailable from other sources (including department
3.3.4 Proposals which request the direct support of research, scholarly, or creative
activities should be submitted to the Organized Research and Creative Activities (ORCA) program. This restriction is not applicable to FDA
request for professional development to enhance knowledge, skills and
agency to develop and eventually execute a research, scholarship, or
3.4 Eligibility of Faculty and Staff
3.4.1 For an FDA proposed activity to be funded by the University, the proposer
must hold a tenured or tenure–track appointment, be a full–time lecturer, or
a professional librarian at the time the proposal is submitted and the
activities of the proposal will be implemented.
3.4.2 FDA funds are discontinued with the termination of appointment to the
3.4.3 Members of the University FDA Committee and/or a Department FDA
Committee are ineligible for funding through the FDA program during any
application cycle in which they serve on these committees.
3.4.4 Applicants must be in good standing with the university at the time of
3.5 Proposal Review
3.5.1 Department FDA Committees: Each academic department from which an
FDA proposal originates must assemble a Department FDA Committee.
The committee is appointed by the department chair. The committee to the
extent possible should represent a range of disciplines from which proposals
may be submitted. The purpose of the Department FDA Committee is to: a)
engage in a review of proposals to ensure there is connection between each
proposal’s activity and the stated objectives of the FDA program; and b) to
offer feedback and time for resubmission to the department committee prior
to submission to the University FDA Committee. The Department FDA
committee makes a recommendation on a proposal (via the
Recommendation and Signature Form) but does not serve to render a
decision of whether or not an application moves forward for review by the
University FDA Committee.
3.5.2 The Department Chair and Dean: The Department Chair and Dean make a
recommendation on a proposal (via the Recommendation and Signature
Form) but does not serve to render a decision of whether or not an
application moves forward for review by the University FDA Committee. The Department Chair does not serve to render a judgement on whether or
not the proposal moves forward to the Dean.
3.5.3 University FDA Committee: The University FDA Committee consists of
two T/TT faculty representatives from each college, up to one lecturer from
each of the five colleges, and one eligible staff member from the university
library. Lecturers may choose whether to accept an invitation to serve on
the University FDA Committee with consideration of the terms of their
appointment. Selection of the committee members is left to the discretion of
colleges and departments. Members of the University FDA Committee will
serve two–year staggered terms. The AVP–FRSP will convene the
committee, provide instructions and an overview of pertinent operating
parameters, provide administrative support, and oversee the election of a
committee chair. Review by the University FDA Committee will be based
on the criteria set forth in the Faculty Development Committee Criteria for
Evaluation Proposal rubric.
3.6 Grants and Expenditures of FDA Funds
3.6.1 The University FDA Committee may suggest that an FDA recipient be
granted an amount greater or less than the original amount requested by
the proposer. There are no limits on suggesting a lower award than
3.6.2 Use of FDA funds must comply with all regulations of the University of
Houston System, UHD, the state, and the federal government.
3.6.3 Proposed activities requiring city, state, or federal permits must provide
copies of the required permits to the AVP–FRSP before funds will be
3.6.4 No single award may be greater than 10% of the FDA funds available in
3.6.5 Funds awarded for designated uses (for example, the purchase of
software) may not be re–budgeted into another category unless approved
in advance by the AVP–FRSP.
3.6.6 All expenditures from faculty FDA accounts must be approved by the
faculty member, department business administrator, and the college
3.6.7 All FDA funds awarded to a faculty member must be expended within
three long semesters from the date of notification of the award.
Unexpended funds at the end of this period will be returned to the
University. Requests for no-cost-extensions to FDA awards should be
directed to the AVP-FRSP.
3.6.8 If the SVPAA/Provost determines any modifications to the
recommendations need to be made, they will consult the university FDA
3.7 Required FDA Reports
3.7.1 Within 18 months of the end of the semester in which the FDA notification
of award is received, the recipient will submit a final report summarizing
the results of the FDA activities funded by the grant to the Provost and AVP
–FRSP using the format described in the Format For FDA Final Report.
3.7.2 In the report, award recipients are required to describe the product, outcome
or deliverables generated from the project funded by the FDA.
3.7.3 The AVP–FRSP will archive all final reports of FDA recipients and will
make them available to the university community upon request.
3.7.4 FDA recipients also may be required to present the findings or products of
this project to the university community at a forum to be determined by the
3.7.5 Award recipients are ineligible for future FDA funds until a report is
4.1 For proposal submission and review process and timeline see the “Procedures and
Timeline” table below in section
4.2. If any due date falls on a holiday, the due
date is moved to the next work day.
4.2 Procedures and timeline table.
|By the first Monday in May||Each academic department will have formed
their Department FDA Committee and will
have selected and announced the name of the
individual who will serve as chair of the
committee. The Senate will follow Faculty Senate procedures to complete the elections
for each department’s representative to the
University FDA Committee; the Senate will
send the names to the AVP–FRSP and the
|By the second Monday in September||The AVP–FRSP will distribute a call for FDA
proposal submission with reference to the
proposal guidelines. The call for proposals
will also contain the deadline for proposal
|By the second Monday in October||Proposer submits proposal to the Department
FDA Committee. [Note: Prior to the fourth
Monday in September, any revisions and
review at this level should be completed by all
parties including the Department FDA
committee chair, the Department Chair, and
the College Dean.] By this date also, the
University FDA Committee should have met
and elected a chair.|
|By the third Monday in October||Department FDA Committee provides written
feedback to the applicant.|
|By the third Thursday in October||The applicant resubmits the proposal to the
Department FDA Committee either
addressing the feedback or providing a written
statement attached to the proposal on why the
feedback was not addressed. The Department
FDA Committee considers the resubmitted
material in its entirety for the
Recommendation and Signature Form.|
|By the first Monday in November||Applicant submits final proposal to
Department Chair, College Dean, and the
AVP–FRSP (who will record the submission,
ensure that it meets regulatory requirements
for funding given in section 3.5, and forward
it to the University FDA Committee).
Department FDA Committee also forwards
the Recommendation and Signature Form to
Department Chair who then sends to College
|By the second Monday in November||The Dean submits the Recommendation and Signature Form to the AVP–FRSP, who
forwards it to the University FDA Committee.|
|By the last Monday in November:||The University FDA Committee sends its
funding recommendations to the AVP–FRSP
with a cover letter from the committee chair
and spreadsheet in which each proposal is listed in rank order from highest priority for
funding (top) to lowest priority for funding.|
|By the second Monday in December:||The Provost will notify each applicant, the
Chair of the University FDA Committee, all
department chairs, and all college deans of
funding decisions. The AVP–FRSP will send
the Recommendation and Signature Form and
justification statements to all applicants.|
|By the third Monday in December:||The Provost will announce the names and
project titles of all FDA recipients to the UHD
5.1 Responsible parties: Associate Vice President for Faculty, Research and
5.2 Review: Every three years on or before May 1st.
5.3 Signed original on file in Employment Services and Operations.
No prior issues of this policy.
Format for FDA Request
Form Format for FDA Final Report
Recommendation and Signature Form
Faculty Development Committee Criteria for Evaluating